Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy

Gut

Volumn 59, Issue 10, 2010, Pages 1340-1346

  Loras, C ^a   Gisbert, J P ^b,c   Minguez M ^d   Merino, O ^e   Bujanda, L ^c,f   Saro, C ^g   Domenech, E ^c,h   Barrio, J ⁱ   Andreu, M ^j   Ordas I ^c,k   Vida, L ^l   Bastida, G ^c,m   Gonzalez Huix F ⁿ   Piqueras, M ^o   Ginard, D ^p   Calvet, X ^c,q   Gutierrez A ^c,r   Abad, A ^s   Torres, M ^t   Panes J ^c,k   Chaparro, M ^b,c   Pascual, I ^d   Rodriguez Carballeira, M ^a   Fernandez Banares F ^a   Viver, J M ^a   Esteve, Maria ^a   more..

^a HOSPITAL MÚTUA DE TERRASSA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL DE CRUCES   (Spain)

^f UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^g HOSPITAL DE CABUEÑES   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^j HOSPITAL DEL MAR   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

^l HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^m HOSPITAL UNIVERSITARIO LA FE   (Spain)

ⁿ HOSPITAL JOSEP TRUETA   (Spain)

^o Department of Gastroenterology Consorci de Terrassa ^*  (Spain)

^p HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^q HOSPITAL DE SABADELL   (Spain)

^r HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^s Hospital de Sant Llorenç   (Spain)

^t HOSPITAL DE L ESPERIT SANT   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADEFOVIR; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INFLIXIMAB; LAMIVUDINE; METHOTREXATE; TACROLIMUS; VIRUS RNA; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENTERITIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; ULCERATIVE COLITIS; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDY; OPPORTUNISTIC INFECTIONS; PHYSIOLOGY; SPAIN; VIROLOGY; VIRUS ACTIVATION;

ADULT; DRUG-INDUCED LIVER INJURY; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; SPAIN; VIRUS ACTIVATION;

EID: 77957188851     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.208413     Document Type: Article

References (34)

1. Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008;22:117-26.
2. Vento S, Cainelli F, Longhi MS. Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002;3:333.
3. Vantes CA, Amarante H, Ioshii SO, et al. Hepatitis C virus in long-term bone marrow transplant survivors. Bone Marrow Transplant 2004;33:1181-5.
4. Esteve M, Saro C, González-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5.
5. del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004;10:701-2.
6. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005;50:163-6.
7. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-6.
8. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007;13:508-9.
9. Esteve M, Loras C, González-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007;13:1450-1.
10. Zein NN. Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22.
11. Rahier JF, Ben-Horin S, Chowers Y, et al. on behalf of the European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis (JCC) 2009;3:47-91.
12. Hutfless SM, Weng X, Liu L, et al. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003. Gastroenterology 2007;133:1779-86.
13. Loras C, Saro C, Gonzalez-Huix F, et al. GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa). Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009;104:57-63.
14. Ferreira-Gonzalez A, Shiffman ML. Use of diagnostic testing for managing hepatitis C virus infection. Semin Liver Dis 2004;24:9-18.
15. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
16. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis 1986;6:97-106.
17. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134:929-36.
18. Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009;28:331-7.
19. Campbell S, Ghosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001;13:191-2.
20. Biancone L, Del Vecchio Blanco G, Pallone F, et al. Italian Group for the Study of the Colon and Rectum. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002;122:593-4.
21. Holtmann MH, Galle PR, Neurath MF. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. Am J Gastroenterol 2003;98:504-5.
22. Katz LH, Fraser A, Gafter-Gvili A, et al. Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and metaanalysis. J Viral Hepatol 2008;15:89-102.
23. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
24. Domènech E, Esteve M, Gomollón F, et al. Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa. GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease. Gastroenterol Hepatol 2005;28:126-34.
25. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009;27:605-11.
26. Raimondo G, Navarra G, Mondello S, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008;48:743-6.
27. Manzini P, Girotto M, Borsotti R, et al. Italian blood donors with anti-HBc and occult hepatitis B virus infection. Haematologica 2007;92:1664-70.
28. Raffa G, Maimone S, Cargnel A, et al. Analysis of occult hepatitis B virus infection in liver tissue of HIV patients with chronic hepatitis C. AIDS 2007;21:2171-5.
29. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-6.
30. Vallet-Pichard A, Pol S. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection. J Hepatol 2006;44:S28-34.
31. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009;29:89-99.
32. McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology 2009;49:S45-55.
33. Iacob S, Cicinnati VR, Hilgard P, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: model to predict HCV cirrhosis after liver transplantation. Transplantation 2007;84:56-63.
34. Beckebaum S, Sotiropoulos GC, Klein CG, et al. Predictive factors of outcome in patients transplanted for hepatitis B. Transplantation 2009;87:872-81.